Prostate Cancer

Cytoreductive Surgery for Metastatic PCa Linked to More Complications

Cytoreductive Surgery for Metastatic PCa Linked to More Complications

By

Cytoreductive radical prostatectomy (RP) for metastatic prostate cancer (PCa) is associated with higher complication rates and longer hospital stays than RP for non-metastatic PCa.

The Potential Role for PARP Inhibitors in Prostate Cancer

The Potential Role for PARP Inhibitors in Prostate Cancer

Identification of DNA repair defects within prostate cancer tissue may enable a precision oncologic approach to treatment.

Persistent Cancer Screening Gaps Revealed in New CDC Report

Persistent Cancer Screening Gaps Revealed in New CDC Report

From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.

Use of Post-RP High Dose Radiotherapy Increasing

Use of Post-RP High Dose Radiotherapy Increasing

By

Physicians increasingly are prescribing high dose and very high dose radiation therapy after radical prostatectomy despite an absence of randomized trials supporting the practice.

First-Line Enzalutamide May Confer a Survival Benefit for mCRPC

First-Line Enzalutamide May Confer a Survival Benefit for mCRPC

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

By

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

By

Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

By

Radiation therapy dose escalation, pelvic lymph node irradiation, and hormone therapy duration are prescribed based on patient and tumor characteristics.

Prostate Cancer Risk Reduced in Men with Very Low Free Testosterone

Prostate Cancer Risk Reduced in Men with Very Low Free Testosterone

By

Men in the bottom 10th of free testosterone level vs those with higher levels were found to have a 23% decreased risk of prostate cancer.

Study Supports Prostate Cancer Active Surveillance for Younger Men

Study Supports Prostate Cancer Active Surveillance for Younger Men

By

Younger men with prostate cancer are less likely to experience Gleason score upgrading and pathologic progression on repeat biopsy.

Salvage RARP Feasible, Effective

Salvage RARP Feasible, Effective

By

According to researchers, 57.3% of men who underwent salvage robot-assisted radical prostatectomy were pad-free at 12 months.

Shorter ADT Course May Suffice for High-Risk Prostate Cancer

Shorter ADT Course May Suffice for High-Risk Prostate Cancer

By

New study shows no significant difference in overall survival between 18 and 36 months of androgen deprivation therapy used in combination with radiation therapy.

Aggressive Therapy Warranted for Gleason 10 Prostate Cancer

Aggressive Therapy Warranted for Gleason 10 Prostate Cancer

By

Regardless of treatment modality, men with Gleason 10 prostate cancer have high 5-year overall survival rates, new study finds.

PET/CT May Improve Imaging of Recurrent Prostate Cancer

PET/CT May Improve Imaging of Recurrent Prostate Cancer

By

Early study results are encouraging, but high-quality data that validate PET/CT against a reliable reference standard are lacking.

Adding MRI Does Not Boost Prostate Cancer Upgrading Rate

Adding MRI Does Not Boost Prostate Cancer Upgrading Rate

By

MRI with targeted prostate biopsy plus systematic biopsy fails to improve detection of upgrading in men on active surveillance for prostate cancer vs systematic biopsy alone.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

Prostate Cancer ADT Ups Thromboembolic Event Risk

Prostate Cancer ADT Ups Thromboembolic Event Risk

By

Pulmonary embolism is associated with GnRH agonist use and orchiectomy.

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa

The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.

Advanced Prostate Cancer Variant More Common Than Thought

Advanced Prostate Cancer Variant More Common Than Thought

Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17% among those with mCRPC.

Focal HIFU Effective Over 5 Years for PCa

Focal HIFU Effective Over 5 Years for PCa

By

Failure-free survival was 88% at 5 years among patients with nonmetastatic prostate cancer who underwent focal therapy with high-intensity focused ultrasound.

Automated Bone Scan Index Prognostic for Prostate Cancer

Automated Bone Scan Index Prognostic for Prostate Cancer

aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer

Conservative Management Up for Low-Risk Prostate Cancer in Veterans

Conservative Management Up for Low-Risk Prostate Cancer in Veterans

More conservative management and active surveillance utilized at VA hospitals from 2005 to 2015.

Metformin Added to Prostate Cancer ADT Ups Survival

Metformin Added to Prostate Cancer ADT Ups Survival

By

Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.

Enzalutamide Delays Metastasis in CRPC

Enzalutamide Delays Metastasis in CRPC

By

Men receiving enzalutamide plus ADT had a significant 71% lower risk for metastasis or death compared with men receiving placebo plus ADT.

Testosterone Levels May Be Determined in Childhood

Testosterone Levels May Be Determined in Childhood

By

Children who migrated to the UK from Bangladesh before puberty and Bangladeshis born in the UK had significantly higher levels of testosterone compared with life-long residents of Bangladesh.

Prostate Cancer Vaccine Found Not to Improve Survival

Prostate Cancer Vaccine Found Not to Improve Survival

By

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

PIVOT Study Results Challenged

PIVOT Study Results Challenged

By

Researchers question the generalizability of a major study showing no significant difference in cancer-specific and overall survival between surgery and observation for localized prostate cancer.

End-of-Life Prostate Cancer-Related Complications Characterized

End-of-Life Prostate Cancer-Related Complications Characterized

By

Men with advanced prostate cancer at diagnosis have an elevated risk of spinal cord compression, renal failure, and other cancer-related morbidities.

Prostate Biopsy Complications Deter Patients From Re-Biopsy

Prostate Biopsy Complications Deter Patients From Re-Biopsy

By

Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.

 Long-Term Data Support Finasteride for PCa Prevention

Long-Term Data Support Finasteride for PCa Prevention

By

Clinicians can rest easier about recommending finasteride to more men, according to experts.

Sign Up for Free e-newsletters